Figure (Invega 01)
Invega Trinza Injection, Suspension, Extended Release
Product Images NDC 50458-606
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Invega Trinza (NDC 50458-606). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Janssen Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Invega 02)
Figure (Invega 03)
This is a list of medical supplies, including a syringe tip, rubber cap, luer connection, needle sheath, needle pouch, and a size specification of 226x1/2".*
Figure (Invega 04)
Figure (Invega 05)
Figure (Invega 06)
Figure (Invega 07)
Figure (Invega 08)
Figure (Invega 09)
Figure (Invega 10)
This text provides instructions on how to dispose of a used needle safely by immediately discarding it in an approved sharps container and not saving it for future use.*
Figure (Invega 11)
This text provides instructions on how to properly shake a medication with a syringe. It is important to shake the medication vigorously for at least 15 seconds with a loose wrist to ensure a homogeneous suspension. If more than 5 minutes pass before injection, vigorous shaking is required again to re-suspend the medication. This medication requires longer and more vigorous shaking than the 1-month paliperidone palmitate extended-release injectable suspension.*
Figure (Invega 12)
Figure (Invega 13)
Figure (Invega 14)
Figure (Invega 15)
Figure (Invega 16)
Figure (Invega 17)
Figure (Invega 18)
Figure (Invega 19)
Figure (Invega 20)
Figure (Invega 21)
Thin wall safety needles are specialized for use with INVEGA TRINZA® and should be disposed of after use rather than saved.*
Chemical Structure (Invega 22)
Figure 1 (Invega 23)
This text describes medication interactions with INVEGA TRINZA, a drug with known pharmacokinetics. The text lists two drugs, Paroxetine, which inhibits the enzyme CYP2D6, and Carbamazepine, which induces the enzyme CYP3A4. The text also mentions Divalproex Sodium ER, but does not provide information about its effect. The remainder of the text contains data about the fold change and confidence intervals in INVEGA TRINZA pharmacokinetics when other drugs are present, specifically changes in the area under the curve (AUC) and maximum concentration (Cmax).*
Figure 2 (Invega 24)
Figure 3 (Invega 25)
This text describes a pharmacokinetic study conducted to evaluate the effect of intrinsic factors on the pharmacokinetics of INVEGA TRINZA. The study investigates the fold change and 90% confidence interval of the drug in various conditions such as renal and hepatic impairment, different age groups, and compares them against normal conditions. The results are shown in the form of AUC and Cmax values. The study aims to provide insight into the effect of intrinsic factors on the drug's efficacy and safety.*
Figure 4 (Invega 26)
Principal Display Panel (273 mg Syringe Carton)
This is a package insert for Invega Trinza, a single-dose prefilled syringe containing paliperidone palmitate, an extended-release injectable suspension for intramuscular injection only. It must be administered by a healthcare professional as it is only available via Rx (prescription). The syringe should be shaken vigorously for at least 15 seconds before being used. It should be stored at room temperature and used in its entirety per injection. There are some characters that make it difficult to fully understand the meaning of some parts of the text.*
Principal Display Panel (410 mg Syringe Carton)
Principal Display Panel (546 mg Syringe Carton)
This is a description of Invega Trinza, an extended-release injectable suspension used for intramuscular injection only. It includes a single-dose prefilled syringe that should be shaken before use. Each injection must be administered by a healthcare professional. The recommended dosage instructions should be viewed in the accompanying package insert. It can be stored between 15°C and 30°C. The text also includes various codes and numbers, which are not relevant to the general description.*
Principal Display Panel (819 mg Syringe Carton)
This is a description of a drug called Invega Trinza®. It is an extended-release injectable suspension that must be administered by a healthcare professional for intramuscular injection only. The recommended dosage is to administer it every three months. The contents include a single-dose prefilled syringe, two needles, and the drug itself in 819mg/2.63mL concentration. There is a warning to shake the syringe vigorously before administering the drug. The accompanying full package insert provides the recommended dosage instructions. The drug should be stored at room temperature between 20°C to 25°C (68°F to 77°F). However, most of the text is not legible text, and hence the message is incomplete.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
